SBIR Phase II: Electrical Property Detection of Residual Cancer in the Surgery Suite

SBIR 第二阶段：手术室中残留癌症的电特性检测

• 批准号: 1058413
• 负责人: William Gregory
• 金额: $ 49.81万
• 依托单位: NovaScan LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-02-01 至 2015-04-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1058413&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Electrical; Property

This Small Business Innovation Research (SBIR) Phase II project aims to bring to market a hand-held probe used by the surgeon to ascertain that the surgical wound and regional lymph nodes are clear of cancer. This technology will provide a highly innovative, rapid and accurate device for detecting cancerous tissue by interrogating the electrical properties of the tissues. Currently, removal of affected tissue must be confirmed in the pathology laboratory resulting in delays of up to 36 hours. If the residual cancer is left undetected the patient may be subjected to multiple surgeries or worse, may have a reoccurrence of the disease. This innovative technology will provide surgeons with a tool to ensure all cancer is removed, assist pathologists to help identify malignancies, and provide better results for breast surgery patients to avoid second or third surgeries.The broader impacts of this research will be the development and implementation of a novel, accurate, rapid, inexpensive, non-invasive, low power, hand-held probe that can assist the surgeon in the removal of all of the cancerous tissue and assist the pathologist in the diagnosis of specific tumor regions. Cancer is a major health problem in the US with over 1.4 million new cases and 560,000 deaths at a cost of $72 billion each year. In particular, the detection of breast cancer has serious drawbacks: cancer is hard to find in dense breast tissue, often depend on the use of invasive contrast agents, and advanced detection technologies are expensive and not available to the entire population. In addition, some types of tumors are not easily identifiable. Surgical procedures are safe only if all cancer is removed. Clearly, there is a pressing need for new technologies that would improve the detection of cancerous tissue.

这个小企业创新研究 (SBIR) 第二阶段项目旨在将一种手持式探头推向市场，供外科医生使用，以确定手术伤口和区域淋巴结是否有癌症。该技术将提供一种高度创新、快速且准确的设备，通过询问组织的电特性来检测癌组织。目前，受影响组织的切除必须在病理实验室进行确认，从而导致长达 36 小时的延误。如果残留的癌症未被发现，患者可能会接受多次手术，或更糟的是，可能会出现疾病复发。这项创新技术将为外科医生提供一种工具，确保所有癌症均被切除，协助病理学家帮助识别恶性肿瘤，并为乳腺手术患者提供更好的结果，以避免第二次或第三次手术。这项研究的更广泛影响将是开发和实施一种新颖、准确、快速、廉价、非侵入性、低功率、手持式探头，可以帮助外科医生切除所有癌组织，并协助病理学家 特定肿瘤区域的诊断。癌症是美国的一个主要健康问题，每年有超过 140 万新发病例和 56 万人死亡，造成的损失达 720 亿美元。尤其是乳腺癌的检测存在严重的缺陷：在致密的乳腺组织中很难发现癌症，通常依赖于侵入性造影剂的使用，而且先进的检测技术价格昂贵且不适用于整个人群。此外，某些类型的肿瘤不容易识别。只有切除所有癌症，手术才是安全的。显然，迫切需要能够改善癌组织检测的新技术。